Case: Jazz Pharmaceuticals, Inc.

Attorneys: Pamela A. Mayer

October 19, 2011 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Palo, Alto, California-based Jazz Pharmaceuticals Inc. (“Jazz Pharmaceuticals” or “Company”) (Nasdaq: JAZZ) for potential violations of the federal securities laws. Investors who purchased the Company’s common stock may be affected.

On October 18, 2011, an FDA warning letter to Jazz Pharmaceuticals dated October 11, 2011 was made public. The letter indicates that the Company was inspected by the FDA from April 27, 2011 through May 6, 2011 and that the FDA had previously provided the Company with the FDA’s inspectional observations in a document dated May 20, 2011.

Among other things, the letter states that Jazz Pharmaceuticals failed to properly submit reports and develop adequate written procedures on serious adverse drug events. The letter also states that Jazz Pharmaceuticals “failed to submit seventy-four (74) serous unexpected [adverse event reports] within 15 calendar days of initial receipt between the time period of January 2003 through December 2010.”

On October 18, 2011, Jazz Pharmaceutical’s common stock declined by $2.68 per share, or 6.2%, to close at $40.34 per share on heavy trading volume.

If you purchased Jazz Pharmaceuticals common stock and would like to discuss our investigation, please e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it .